Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | ERN1 | O75460 | 1/20 | 0.34 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25520437 | 0.83 | ALDH1A1 (0.35) | CES2CES1ALDH1A1SMN1; SMN2KIF11 | |
| SCHEMBL29655021 | 0.83 | ALDH1A1 (0.35) | CES2CES1ALDH1A1SMN1; SMN2KIF11 | |
| SCHEMBL19125728 | 0.83 | SRC (0.41) | ALDH1A1SMN1; SMN2TUBB1KIF11CYP2A6 | |
| SCHEMBL18002614 | 0.83 | KDM4E (0.46) | CES2CES1ALDH1A1SMN1; SMN2TUBB1 | |
| SCHEMBL19748916 | 0.83 | ALDH1A1 (0.35) | CES2CES1ALDH1A1SMN1; SMN2KIF11 | |
| SCHEMBL29950733 | 0.83 | SRC (0.41) | ALDH1A1SMN1; SMN2TUBB1KIF11CYP2A6 | |
| SCHEMBL19136810 | 0.83 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2KIF11 | |
| SCHEMBL6738427 | 0.80 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2KIF11CYP2A6ERN1 | |
| SCHEMBL1811153 | 0.80 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2KIF11CYP2A6ERN1 | |
| SCHEMBL4331082 | 0.79 | KIF11 (0.49) | ALDH1A1SMN1; SMN2KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 862 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120035228-A | Polyimide composite film for flexible cover plate of space solar cell | 东南大学 | 2025-05-23 | — | — | CN | claimed |
| CN-120005333-A | Wear-resistant environment-friendly incombustible decorative plate and preparation method thereof | 临沂华特装饰材料有限公司 | 2025-05-16 | — | — | CN | claimed |
| CN-119875052-A | Ion polymer based on flexible main chain, anion exchange membrane and preparation method thereof | 武汉轻工大学 | 2025-04-25 | — | — | CN | claimed |
| CN-119424664-A | Tumor microenvironment response pharmaceutical composition and preparation method and application thereof | 北京大学 | 2025-02-14 | — | — | CN | claimed |
| CN-118879381-B | Lubricating grease composition for bearing and preparation method thereof | 广东法航实业有限公司 | 2025-01-28 | — | — | CN | claimed |
| CN-119350148-A | Synthesis method of 3,4, 5-trifluoro benzaldehyde | 蒲城驭腾新材料科技有限公司 | 2025-01-24 | — | — | CN | claimed |
| CN-118459420-A | Thiazolinone compound containing multiple halogen atoms and preparation method thereof | 南京工业大学 | 2024-08-09 | — | — | CN | claimed |
| CN-118459422-A | Thiazole thiazolinone compound containing multiple halogen atoms and preparation method thereof | 南京工业大学 | 2024-08-09 | — | — | CN | claimed |
| CN-118085334-A | High-tensile swelling-resistant polyvinyl alcohol-based hydrogel and preparation method and application thereof | 国科广化(南雄)新材料研究院有限公司 | 2024-05-28 | — | — | CN | claimed |
| CN-116284017-B | Method for preparing amide compound by utilizing enzyme-like efficient catalytic oxidation | 中国科学院青岛生物能源与过程研究所 | 2024-03-22 | — | — | CN | claimed |
| US-9840508-B2 | N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a] pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders | OGED SA (BE) | 2017-12-12 | — | — | US | claimed |
| US-20170306217-A1 | METHOD AND COMPOSITIONS FOR HYDRAULIC FRACTURING AND FOR TRACING FORMATION WATER | NCS Multistage, LLC | 2017-10-26 | — | — | US | claimed |
| US-20160304521-A1 | NOVEL N-ACYL-(3-SUBSTITUTED)-5,6,7,8-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS | OGEDA SA (BE) | 2016-10-20 | — | — | US | claimed |
| US-20160289233-A1 | NOVEL N-ACYL-(3-SUBSTITUTED)-(8-METHYL)-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-a] PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS | EUROSCREEN SA (BE) | 2016-10-06 | — | — | US | claimed |
| CN-104151150-B | A kind of preparation method of 3,4-bis-(3,4,5-trifluorophenyl)-2,5-diphenyl cyclopentadienone | 山东大学 | 2016-08-24 | — | — | CN | claimed |
| US-9422299-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists | EUROSCREEN SA (BE) | 2016-08-23 | — | — | US | claimed |
| CN-102906093-B | NK-3 receptor selective antagonists compound, pharmaceutical composition and the using method in the receptor-mediated disease of NK-3 | EUROSCREEN S.A. (BE) | 2016-01-13 | — | — | CN | claimed |
| CN-104447351-A | Fluorine-containing diamine monomer with large side group and non-coplanar structure and preparation method of fluorine-containing diamine monomer | UNIV GUILIN TECH GUT | 2015-03-25 | — | — | CN | claimed |
| CN-104151150-A | Preparation method of 3,4-di(3,4,5-trifluorophenyl)-2,5-diphenylcyclopentyldienone | UNIV SHANDONG | 2014-11-19 | — | — | CN | claimed |
| CN-102906093-A | Novel nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders | EUROSCREEN SA | 2013-01-30 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160289233-A1 | NOVEL N-ACYL-(3-SUBSTITUTED)-(8-METHYL)-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-a] PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS | GPR3, KCNK3, ACKR3 | CES2 4281/4885CES1 2250/4885ALDH1A1 2828/4885 |
| US-20160304521-A1 | NOVEL N-ACYL-(3-SUBSTITUTED)-5,6,7,8-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS | KCNK3, GPR3, ACKR3 | CES2 4028/4885CES1 1895/4885ALDH1A1 2772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.